Mainolfi Nello

About Mainolfi Nello

Nello Mainolfi is the Founder, President, and Chief Executive Officer of Kymera Therapeutics, a U.S.-listed biopharmaceutical company focused on targeted protein degradation. He is also a member of the company’s board of directors. Public company materials show that he has been a co-founder of Kymera and that his responsibilities expanded over time as the company matured, including service as Chief Scientific Officer and later President before he was appointed CEO in 2019. ([kymeratx.com](https://www.kymeratx.com/about-us/leadership/nello-mainolfi-phd/?utm_source=openai)) Before founding Kymera, Mainolfi built his career in drug discovery. He worked at the Novartis Institutes for Biomedical Research, where he led teams that identified multiple novel drug candidates that advanced into clinical development. Public biographies also note that he led the discovery and development of the first complement factor B inhibitor, now in late-stage clinical development across several indications. Prior to Kymera, he served as an Entrepreneur in Residence at Atlas Venture and previously led discovery research at the cancer metabolism company Raze Therapeutics. ([theorg.com](https://theorg.com/org/kymera-therapeutics/org-chart/nello-mainolfi?utm_source=openai)) His background is rooted in medicinal chemistry, synthetic chemistry, and translational drug discovery. Public profiles state that he has authored more than 60 papers and patents, reflecting a research-heavy career that bridges scientific innovation and company building. That mix of scientific depth, startup leadership, and venture exposure has been central to his role in shaping Kymera’s platform-based strategy in protein degradation. ([theorg.com](https://theorg.com/org/kymera-therapeutics/org-chart/nello-mainolfi?utm_source=openai)) As a corporate executive, Mainolfi has been associated with Kymera’s evolution from a founding idea into a clinical-stage biotech company. Company communications credit him with strategic leadership as Kymera progressed its drug discovery engine into development and expanded its pipeline. Where public disclosures do not provide granular detail on specific business decisions, it is safest to describe his contributions in broad terms: founder-level leadership, scientific strategy, pipeline advancement, and company scaling. ([prnewswire.com](https://www.prnewswire.com/news-releases/kymera-therapeutics-promotes-nello-mainolfi-phd-to-chief-executive-officer-300961452.html?utm_source=openai))